Advised TeneoBio in $900 Million Sale to Amgen

Served as intellectual property counsel to TeneoBio, Inc. in connection with its acquisition by Amgen. Under the terms of the agreement, which the companies announced July 27, Amgen will acquire all outstanding shares of TeneoBio at closing in exchange for a $900 million upfront cash payment, as well as future contingent milestone payments to TeneoBio equity holders potentially worth up to an additional $1.6 billion in cash.